搜尋結果
AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen.
China is the third country to launch LEQEMBI following the United States and Japan. LEQEMBI selectively binds to soluble Aβ aggregates (protofibrils*), as well as insoluble Aβ aggregates (fibrils) which are a major component of Aβ plaques in AD, thereby reducing both Aβ protofibrils and Aβ plaques in the brain.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the global revenue of the anti-amyloid-beta protofibril antibody LEQEMBI® in the fourth quarter of fiscal year 2023 (January 1, 2024 – March 31, 2024) was JPY 2.83 billion (pre-audit basis), which was approximately 2.7 times higher than the revenue in ...
AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen.
Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that TIME has selected Eisai as one of the TIME100 Most Influential Companies of 2024. TIME reveals the TIME100 Most Influential Companies list, highlighting companies making an extraordinary impact around the world.
TOKYO and CAMBRIDGE, Mass., June 10, 2024 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that that the U.S. Food and Drug Administration (FDA) has accepted Eisai’s Supplemental Biologics L...
TOKYO and CAMBRIDGE, Mass., May 15, 2024 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has initiated the rolling submission of a Biologics License Application (BLA) to the U.S....
